HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review

This article was originally published in The Tan Sheet

Executive Summary

FDA's regulatory framework for removing dangerous dietary supplements from the market under the Dietary Supplement Health & Education Act's "unreasonable risk" standard will be issued shortly by the agency

You may also be interested in...

Supreme Court Refuses Ephedra Case, Battle Against Risk-Benefit Continues

Challenges to the risk-benefit analysis FDA applied in banning the use of ephedra will continue following the Supreme Court's May 14 refusal to hear Nutraceutical Corp.'s appeal, according to the firm's attorney and to industry trade groups

Dingell Challenged To Document Reasons For Supplement Safety Doubts

The president of Jarrow Formulas has formally challenged House Energy and Commerce Committee Chairman John Dingell, D-Mich., to back up claims that dietary supplements "are killing people," and says he does not expect Dingell will act on plans to conduct hearings on the Dietary Supplement Health and Education Act

NVE Takes First Shot At Ephedra Ban: FDA Violated DSHEA, Firm Says

NVE Pharmaceuticals is challenging FDA's ban of ephedra on the grounds the agency did not meet its burden of proving the ingredient unsafe under the Dietary Supplement Health & Education Act

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts